Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer

Trial Profile

Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms BREC
  • Most Recent Events

    • 22 Nov 2018 Results assessing association of PALB2 messenger RNA expression with platinum-docetaxel efficacy published in the Journal of Thoracic Oncology.
    • 31 May 2013 Planned interim results (cut-off 15 October 2012; n=279) presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 Based on the negative results for PFS at the interim analysis, accrual has been closed according to the abstract presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top